Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus METHYCLOTHIAZIDE AND DESERPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus METHYCLOTHIAZIDE AND DESERPIDINE.
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs METHYCLOTHIAZIDE AND DESERPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral vascular resistance via relaxation of vascular smooth muscle, possibly by interfering with calcium transport. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
Initially one capsule (25 mg hydralazine/25 mg hydrochlorothiazide, or 50 mg hydralazine/50 mg hydrochlorothiazide) twice daily, increase as needed to a maximum of 200 mg hydralazine/200 mg hydrochlorothiazide daily.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
None Documented
None Documented
Hydralazine: 2-8 hours (terminal, prolonged in renal impairment; acetylator phenotype affects clearance; slow acetylators have 2-fold longer half-life). Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment; clinically relevant for once-daily dosing).
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Hydralazine: 90% renal (primarily as metabolites, 10-15% unchanged); Hydrochlorothiazide: >95% renal (unchanged). Biliary/fecal: negligible for both.
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic and Antihypertensive